Background: I-131 has been used in the therapy of well-differentiated thyroid cancer for over
50 years. Although the benefits and risks of I-131 remain issues of controversy and research …

Radioiodine is important in the diagnostic and therapeutic armamentarium of differentiated
thyroid cancer (DTC); however, many controversies persist. This article addresses some of …

Background: Publication of the 2015 American Thyroid Association (ATA) management
guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met …

Background: There is a growing belief that a pretherapy scan yields little or no additional
information that would impact on radioiodine ablation dosing. In addition, there is some …

This is a comprehensive presentation of the risks and benefits of radioiodine-131 in the
treatment of metastatic well differentiated thyroid cancer. In addition, methods to optimize the …

Abstract 131I is an integral component in postsurgical management of well‐differentiated
thyroid cancer (WDTC), which includes papillary and follicular types. 131I is used …

Background: The utility of radioiodine (RAI) scans prior to 131I ablation is controversial. The
objective of this study was to evaluate the utility of RAI scans prior to 131I ablation in patient …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …

Background It is not clear whether the administration of radioiodine provides any benefit to
patients with low-risk thyroid cancer after a complete surgical resection. The administration …

Use of radioactive iodine is an essential adjuvant treatment strategy after thyroidectomy in
patients with differentiated thyroid carcinoma. Although generally safe, radioiodine therapy …